ZINBRYTA Drug Profile

Summary for Tradename: ZINBRYTA

High Confidence Patents:	15
Applicants:	1
BLAs:	1
Recent Clinical Trials:	See clinical trials for ZINBRYTA

Recent Clinical Trials for ZINBRYTA

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
AbbVie	Phase 3
Biogen	Phase 3
Hammersmith Hospitals NHS Trust	Phase 4

See all ZINBRYTA clinical trials

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for ZINBRYTA Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for ZINBRYTA Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Biogen Inc.	ZINBRYTA	daclizumab	Injection	761029		2013-06-25	DrugPatentWatch analysis and company disclosures
Biogen Inc.	ZINBRYTA	daclizumab	Injection	761029		2016-12-07	DrugPatentWatch analysis and company disclosures
Biogen Inc.	ZINBRYTA	daclizumab	Injection	761029		2018-04-03	DrugPatentWatch analysis and company disclosures
Biogen Inc.	ZINBRYTA	daclizumab	Injection	761029		2019-03-31	DrugPatentWatch analysis and company disclosures
Biogen Inc.	ZINBRYTA	daclizumab	Injection	761029		2017-09-03	DrugPatentWatch analysis and company disclosures
Biogen Inc.	ZINBRYTA	daclizumab	Injection	761029		2023-02-13	DrugPatentWatch analysis and company disclosures
Biogen Inc.	ZINBRYTA	daclizumab	Injection	761029		2026-12-08	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for ZINBRYTA Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Biogen Inc.	ZINBRYTA	daclizumab	Injection	761029		2036-12-20	Patent claims search
Biogen Inc.	ZINBRYTA	daclizumab	Injection	761029		2037-03-13	Patent claims search
Biogen Inc.	ZINBRYTA	daclizumab	Injection	761029		2034-01-08	Patent claims search
Biogen Inc.	ZINBRYTA	daclizumab	Injection	761029		2037-02-22	Patent claims search
Biogen Inc.	ZINBRYTA	daclizumab	Injection	761029		2036-08-10	Patent claims search
Biogen Inc.	ZINBRYTA	daclizumab	Injection	761029		2033-11-20	Patent claims search
Biogen Inc.	ZINBRYTA	daclizumab	Injection	761029		2034-01-03	Patent claims search

International Patents for ZINBRYTA

Country	Patent Number	Estimated Expiration
South Korea	101863534
Japan	2014122221
European Patent Office	2758080
World Intellectual Property Organization (WIPO)	2006130599
European Patent Office	2593187
Japan	5259392
South Africa	200810311

Supplementary Protection Certificates for ZINBRYTA

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
CR 2016 00058	Denmark		PRODUCT NAME: DACLIZUMAB; REG. NO/DATE: EU/1/16/1107 20160705
2016/052	Ireland		PRODUCT NAME: DACLIZUMAB; REGISTRATION NO/DATE: EU/1/16/1107 20160701
CR 2016 00057	Denmark		PRODUCT NAME: DACLIZUMAB; REG. NO/DATE: EU/1/16/1107 20160705
93314	Luxembourg		NAME: DACLIZUMAB; AUTHORISATION NUMBER AND DATE: EU/1/16/1107 20160705
C01539200/01	Switzerland		PRODUCT NAME: DACLIZUMAB BETA; REGISTRATION NO/DATE: AUTORISATION SWISSMEDIC 66069 26.01.2017
55/2016	Austria		PRODUCT NAME: DACLIZUMAB; REGISTRATION NO/DATE: EU/1/16/1107 (MITTEILUNG) 20160705
1690055-7	Sweden		PRODUCT NAME: DACLIZUMAB OR A PHARMACEUTICALLY ACCEPTABLE SALT, HYDRATE, OR SOLVATE THEREOF; REG. NO/DATE: EU/1/16/1107 20160705

Market Dynamics and Financial Trajectory for ZINBRYTA (Daclizumab)

Last updated: September 25, 2025

Introduction

ZINBRYTA (daclizumab), a monoclonal antibody developed by Biogen Idec, served as a groundbreaking biologic for multiple sclerosis (MS) management when it launched in 2016. Designed as an immunomodulator targeting interleukin-2 receptor alpha (CD25), ZINBRYTA aimed to address unmet needs in relapsing forms of MS. Despite initial promise, its market presence was short-lived due to safety concerns, leading to its recent market withdrawal. Understanding ZINBRYTA’s market dynamics and financial trajectory reveals insights into the complex life cycle of biologics within highly competitive and safety-sensitive therapeutic niches.

---

Market Introduction and Initial Commercial Dynamics

Launch and Market Positioning

In 2016, ZINBRYTA entered a lucrative but highly competitive MS therapeutics landscape, dominated by multiple monoclonal antibodies, oral agents, and injectable therapies. Biogen marketed ZINBRYTA as an innovative, self-administered biological treatment offering a unique mechanism of action. Its rapid subcutaneous administration (monthly injections) aimed to improve patient adherence compared to more cumbersome infusion-based drugs.

Market Reception

Initial adoption was modest but optimistic. ZINBRYTA's approval by the FDA was based on demonstrating significant reductions in annualized relapse rates (ARR) and MRI lesion activity — comparable to existing MS biologics. Despite robust early sales, uptake was contingent on physician familiarity and patient acceptance, heavily influenced by safety profile perceptions.

Market Dynamics Factors

1. Competitive Landscape:
   The MS biologic market in the U.S. and Europe was crowded by products like Tecfidera, Aubagio, Tysabri, and Gazyva. Introducing a new biologic required demonstrating clear advantages or differentiated safety.

2. Pricing and Reimbursement:
   ZINBRYTA was priced at a premium, with factors like formulary inclusion and insurance coverage impacting sales growth. The lack of a substantial price premium curtailed aggressive market penetration.

3. Patient and Physician Perception:
   Safety concerns emerged early, impacting confidence. Biogen’s marketing emphasized efficacy and convenience, but safety issues became a pivotal factor influencing prescriber behavior.

4. Regulatory and Pharmacovigilance Environment:
   Increased emphasis on post-marketing surveillance meant adverse effects were scrutinized more keenly. This backdrop influenced early perceptions and sales trajectories.

---

Safety Concerns and Market Contraction

Safety Signal Emergence

In 2018, reports of serious adverse effects, including autoimmune encephalitis and liver toxicity, prompted closer review. Particularly, cases of hepatotoxicity and inflammatory brain disease raised red flags.

Regulatory Response

Biogen voluntarily withdrew ZINBRYTA from the market in March 2018 due to safety concerns. The decision was based on the risk-benefit assessment amidst reports of adverse events not outweighing its therapeutic advantages, especially with available alternatives.

Impact on Market Dynamics

• Sales Decline:
  Prior to withdrawal, ZINBRYTA’s sales plateaued and declined sharply. Annual revenues, estimated at over $300 million in 2017, dwindled rapidly after safety alerts.

• Market Exit:
  The withdrawal eliminated potential future revenues and halted the product’s role in the MS biologic segment. This left a void for patients and physicians seeking alternatives, potentially affecting competitors’ market shares.

Post-Withdrawal Market Impacts

The ZINBRYTA case underscored the dominance of safety profiles in biologic adoption within MS. While biologic innovation continues, safety surveillance has become even more critical for similar therapies.

---

Financial Trajectory and Business Implications

Revenue Profile

At peak, ZINBRYTA contributed significantly to Biogen’s portfolio, with estimated revenues around $350 million in 2017. However, its short market presence limited long-term revenue potential.

Cost Considerations

• Development and Marketing:
  The initial R&D investment, along with marketing and education campaigns, was substantial. Once safety signals emerged, additional costs related to pharmacovigilance and regulatory communication arose.

• Post-Warning Financial Impact:
  The market withdrawal resulted in asset impairment charges, impacting Biogen’s earnings. The opportunity cost was significant, given the product’s initial promise.

Strategic Lessons

Biogen’s experience with ZINBRYTA highlights the importance of rigorous safety assessment and post-marketing surveillance. The financial risks associated with unexpected adverse effects can overshadow initial product advantages. Future biologics in the MS space are increasingly subjected to stringent safety protocols before and after launch.

---

Market Outlook Post ZINBRYTA

Resilience of the MS Biologic Market

Despite ZINBRYTA’s exit, the MS biologic market remains robust, with new entrants such as ozanimod (by BMS and Pfizer) and next-generation monoclonal antibodies entering the scene. Market growth is driven by expanding patient populations, improved diagnostics, and the adoption of oral and high-efficacy infusional therapies.

Emerging Trends

• Safety-Focused Innovation:
  Manufacturers are emphasizing safety profiles alongside efficacy, often employing biomarkers and real-world evidence to mitigate risks.

• Personalized Medicine:
  Genetic and biomarker-driven approaches prioritize tailored treatments, reducing trial-and-error in therapy selection.

• Market Repositioning of Failed or Withdrawn Drugs:
  While ZINBRYTA is no longer available, similar biologics may be reevaluated under new formulations or with enhanced safety monitoring.

Therapeutic and Commercial Opportunities

The MS biologic pipeline continues to evolve, with biosimilars and novel modalities promising expanded options. Companies that integrate safety, efficacy, convenience, and affordability will lead market share growth.

---

Key Takeaways

• The initial market success of ZINBRYTA demonstrated the importance of offering differentiable clinical benefits and convenience in a crowded biologic landscape.

• Safety concerns played a decisive role in its rapid market withdrawal, illustrating the critical need for rigorous post-marketing surveillance in biologic therapeutics.

• Financially, ZINBRYTA’s trajectory underscores the volatility associated with innovative biologics; significant revenue potential can be rapidly terminated by safety issues.

• Future biologic developments in MS must prioritize safety alongside efficacy to sustain market presence and investor confidence.

• The broader MS biologic market remains resilient, with ongoing innovation fueled by safety-focused strategies and personalized treatment paradigms.

---

FAQs

1. What led to the discontinuation of ZINBRYTA?
Safety concerns, notably reports of autoimmune encephalitis and hepatotoxicity, prompted Biogen to withdraw ZINBRYTA from the market in 2018 after unfavorable risk-benefit analysis.

2. How did safety issues impact ZINBRYTA’s market potential?
Adverse events undermined physician confidence and patient acceptance, leading to declining sales and ultimately market withdrawal, precluding long-term revenue accumulation.

3. Are there ongoing competitors to ZINBRYTA in the MS biologic space?
Yes. The market features established therapies like Tysabri, Ocrevus, and Mavenclad, along with newer entrants emphasizing safety and efficacy, such as ozanimod and siponimod.

4. What lessons can biotech companies learn from ZINBRYTA’s market dynamics?
Prioritizing safety, comprehensive post-market surveillance, and balancing efficacy with tolerability are essential for sustainable biologic development and commercialization.

5. Could ZINBRYTA’s mechanism of action be utilized in future therapies?
Potentially, but safety modifications or alternative delivery approaches would be necessary. The current focus favors therapies with proven safety profiles to avoid repeat issues.

---

References

[1] Biogen. (2017). ZINBRYTA (daclizumab) prescribing information.
[2] U.S. Food and Drug Administration. (2018). Withdrawal of ZINBRYTA from the market.
[3] IMS Health. (2017). MS biologics market analysis report.
[4] Johnson, D. et al. (2018). Safety analysis of monoclonal antibodies in multiple sclerosis. Neurology Clinical Practice.
[5] MarketWatch. (2020). Biogen’s strategies in the evolving MS therapeutics landscape.